New diabetes pill cofrogliptin takes on acarbose in Head-to-Head trial
NCT ID NCT07122102
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called cofrogliptin against an older drug, acarbose, in 200 adults with type 2 diabetes who have never taken diabetes medication. The goal is to see which drug better lowers blood sugar levels and has fewer side effects. Participants will take one of the two drugs and be monitored for changes in blood sugar over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
He'nan Provincial People's Hospital
Zhengzhou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?